论文部分内容阅读
安徽省科委、卫生厅于1983年8月26日在安徽主持召开了环维黄杨星-D技术鉴定会。参加会议的代表有北京、上海、南京、广州及本省的植化、药理、药检、制剂及临床方面的教授、专家及有关技术人员共58人,其中由11人组成技术鉴定委员会。环维黄杨星-D是从中药小叶黄杨木中提取的生物硷,国内外文献资料均未见用于治疗冠心病的报道。1974年皖南医学院经离体蛙心及在位猫心的药理试验初步发现,黄杨木水煎剂具有强心和扩冠作
The Anhui Science and Technology Commission and the Health Department hosted the Huaiwei Huangyangxing-D technical appraisal meeting on August 26, 1983 in Anhui. Representatives attending the conference included 58 professors, experts and relevant technicians from Beijing, Shanghai, Nanjing, Guangzhou and the province’s phytochemicals, pharmacology, drug testing, preparations, and clinics, of whom 11 were technical appraisal committees. Cyclovirobuxine-D is a biological glycoside extracted from traditional Chinese medicine Cyclovirobuxine, and there are no reports on the treatment of coronary heart disease at home and abroad. In 1974, a preliminary pharmacological test of the isolated frog heart and cat’s heart was found in the Wannan Medical College. The boxwood water decoction had a strong heart and a crown extension.